Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Drug Candidates for the Treatment of Oral Cancer and Oral Cancer Pain"
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 May 2023) | Viewed by 3808
Special Issue Editor
Interests: oral cancer; oral cancer pain; drug discovery; natural compounds; small molecule inhibitors
Special Issue Information
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and its incidence is ever-increasing. The majority (60%) of tumors are located in the oral cavity (oral squamous cell carcinoma; OSCC) and are notoriously diagnosed in advanced stages (stage 3 and 4), resulting in high morbidity and high mortality rates. However, when they are discovered in early stages (stage 1 and 2), there is an 80% five-year survival rate. This is due to improvements in surgical techniques for early disease. In spite of advances in existing therapies and development of new treatment strategies (e.g., targeted therapies and small molecule inhibitors), very few efficacious drugs have been developed over the past 50 years to treat advanced and recurrent oral cancers. Recently, immunotherapies have shown great promise when used in conjunction with other standard therapies (chemo- and radiotherapies); however, the response rates remain relatively low, leaving a very large patient population in need of new therapeutic options. In addition, OSCC is the most painful cancer type there is. These patients rapidly develop tolerance to opioids, the mainstay therapy for oral cancer pain. Hence, many patients are left with no efficacious analgesics while battling this insidious disease. The journal Pharmaceuticals invites both reviews and original articles detailing novel therapeutic targets, drug candidates, and treatment strategies for oral cancer and oral cancer pain. Topics include natural compounds, small molecule inhibitors, immunotherapies, novel targets/biomarkers, drug repurposing, radiotherapy, and targeted therapies. The collection of manuscripts will be published as a Special Issue of the journal.
Dr. Cara B. Gonzales
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- oral cancer
- oral cancer pain
- drug discovery
- natural compounds
- small molecule inhibitors